Drugs, Diseases, and the Managed Care Impact

(D4) Managed Care Approaches to Equitable Access to Recombinant Adeno-Associated Virus (rAAV) Gene Therapy

Thursday, March 23, 2023

9:45 AM – 11:00 AM

Location: 302AB

ACPE UAN:0233-0000-23-007-L01-P | Contact Hours: 1.25 | Activity Type: Knowledge-based

Faculty(s)

Michelle Booth, PharmD (she/her/hers)

Sr. Director, Specialty Clinical Solutions
Magellan Rx Management
Middletown, RI
Andy Killpack, PharmD

Director, Specialty Clinical Solutions
MagellanRx
South Jordan, UT

Moderator(s)

KG

Kimberly Glenn, PhD, MPH

VP HEOR Research Consulting
Optum
Eden Prairie, Minnesota

This activity is supported by an educational grant from Pfizer, Inc.

Gene therapies, such as recombinant adeno-associated virus (rAAV) vector technology, have arrived. Understanding the current and future impact is essential for payers, particularly with growing rAAV gene therapy innovation for rare genetic diseases and the complexities of access, cost, and durability of these therapies. This session will review the existing and pipeline rAAV gene therapy landscape, insights into payer management strategies, and the associated difficulties and solutions related to access for a diverse population.

Learning Objectives::

At the completion of this activity, participants should be able to:

Define the evolution of recombinant adeno-associated virus (rAAV) gene therapy.
Discuss new and emerging advances in the use of rAAV gene therapy based on efficacy, safety, durability, policy, and clinical utilization.
Discuss health disparities related to access to rAAV gene therapy for a diverse population.
Identify managed care strategies that address health disparities and equitable access to rAAV gene therapy for eligible patients.